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Transplantation of Human Embryonic Mesenchymal Stem Cells
Alleviates Lupus Nephritis in MRL/lpr Mice
Li Yuan, Zuo-Tao Xiao, Hui Shi
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
Objective: Compared with bone marrow-derived MSC, embryo-derived MSC
have greater expansion and differentiation potentials. T helper cell 17(Th17)
and interleukin 17(IL-17) is closely related to the occurrence and develop-
ment of Lupus. The glial cell-derived neurotrophic factor (GDNF) which is
closely related to the kidney development is found to be a kidney protection
factor and can increase the renal protective effects of stem cells as well.
Persephin (PSP) is a member of the family of GDNF and also involves in
the kidney development. We investigated the effects of human embryonic
MSC (hMSC) in lupus nephritis in MRL/lpr mice.
Methods: The MRL/lpr mice were divided into 2 groups: Control (nZ 16) and
hMSC (n Z 16) groups. hMSC were injected at one dose of 1 106/200 ul
twice (at the 16th and 19th weeks of age) through tail vein. Mice were sacri-
ficed at 24 weeks of age. Multi-treatment of hMSC was able to increase the
survival, decrease the levels of 24-hour proteinuria, and anti-double-
stranded DNA (dsDNA) antibody.
Results: hMSC treatment alleviated the extent of renal injury such as cres-
cent formation and interstitial inflammatory cell infiltration in MRL/lpr
mice. hMSC treatment also inhibited Th17 cell differentiation in spleen
and decrease the serum level of IL-17. The level of GDNF and PSP was
increased in renal of hMSC treatment MRL/lpr mice.Figure 1. hMSC transplantation alleviates lupus nephritis in MRL/lpr mice.
(A) hMSC treatment prolongs survival (p < 0.01 vs Control). (B) hMSC1561-5413significantly reduced urine protein (*p < 0.05 vs Control). (C) Representative
hematoxylin and eosin staining of renal sections from each group. Original
magnification, 400. (D, E) Western blot analyses showed that hMSC treat-
ment MRL/lpr mice has increased expression of GDNF and PSP (*p < 0.05
vs Control).
Conclusion: These findings indicate that hMSCs transplantation might be a
potentially promising approach in the treatment of lupus nephritis, possibly by
inhibiting Th17 cell differentiation and increasing GDNF and PSP level in renal.http://dx.doi.org/10.1016/j.hkjn.2015.08.128
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Objectives: Adrenomedullin (ADM), a vasodilating peptide comprising 52
amino acids, confers anti-inflammatory properties. Although our previous
study identified a negative association between serum ADM levels and pro-
teinuria in lupus nephritis patients, none has explored the in-vivo effect
of ADM in lupus nephritis. We evaluated the effects of ADM in nephritis,
splenic lymphocytes/macrophages and autoantibody profile in MRL/Faslpr
mice before and after lupus-like disease onset.
Methods: ADM (27 mcg/0.2 ml normal saline [NS]) or 0.2ml NS was adminis-
tered intraperitoneally into 6-week (pre-lupus) and 12-week old (adult
group) MRL/Faslpr mice thrice weekly for 18 and 6 weeks respectively.
Upon treatment completion, urine protein and red cell levels were semi-
quantified. Cervical and axillary lymph nodes (LN) were weighed. Splenic
B (B220+) and T lymphocytes (CD4+ and CD8+) and macrophages (CD11b+)
were enumerated by flow cytometry. Kidneys were studied by immunofluo-
rescence for C3, C1q, anti-dsDNA and immunoglobulins (Ig)A, IgM and IgG de-
positions. Serum anti-dsDNA, -Sm, -ribosomal-P and -SSA/B autoantibodies
were measured by immunoassays. The in-vitro effects of ADM on splenic B
and T cell activation, proliferation and apoptosis were assessed with and
without CpG and anti-CD3/CD28 stimulations for 72 hours.
Results: Proteinuria (p Z 0.007) and LN weight (p Z 0.003) were signifi-
cantly lower in the ADM-treated adult mice than their NS-treated counter-
parts. Lower LN weight (p Z 0.036) but not proteinuria, was noted in the
ADM-treated pre-lupus group than their NS-treated counterparts. Serum
autoantibody levels, and the splenic lymphocyte and macrophage numbers
did not differ between both ADM-treated groups and their respective NS-
treated counterparts. ADM-treated adult mice had significantly reduced
renal Ig and complement depositions than their NS-treated counterparts.
ADM treatment did not alter the activation, apoptosis and proliferation of
splenic lymphocytes in vitro.
Conclusion: Exogenous ADM treatment reduced LN weight, proteinuria
and renal Ig and complement depositions in adult MRL/Faslpr mice
Lupus Nephropathy S47without affecting autoantibody profile, splenic lymphocytes and
macrophages.Table 1. Baseline clinical features of LN patients with class III and III+V.
III III＋V P value
Patients (n) 207 169
Female (n, %) 186 (89.9%) 146 (86.4%) 0.335
LN onset age (years) 30.98.3 30.18.1 0.371
Mean arterial pressure
(mmHg)
95.513.2 99.213.7 0.008
Haemoglobin (g/dl) a 10.52.1 10.92.3 0.053
Haematuria (104cells/ml) 36.0 (3.0-150.0) 11.0 (2.0-50.0) 0.397
24-h urinary protein (g/24h) 1.661.99 3.162.72 <0.001
Serum creatinine (mg/dl) a 0.910.50 0.900.81 0.890
Serum complement C3 (g/L) 0.5980.260 0.6370.287 0.182
Serum complement C4 (g/L) 0.1560.126 0.1670.132 0.401
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.
Table 2. Baseline clinical features of LN patients with class IV and IV+V.
IV IV＋V P value
Patients (n, %) 559 233
Female (n, %) 493 (88.2%) 202 (86.7%) 0.554
LN onset age (years) 31.08.4 30.28.9 0.220
Mean arterial pressure
(mmHg)
101.214.5 100.212.5 0.350
Haemoglobin (g/dl) a 8.92.0 9.32.1＃ 0.018
Haematuria (104cells/ml) 90.0
(15.0-265.0)
60.0
(12.0-187.5)
0.012
24-h urinary protein (g/24h) 3.412.92 4.193.10 <0.001
Serum creatinine (mg/dl) a 1.481.33 1.341.21 0.077
Serum complement C3 (g/L) 0.5050.269 0.4860.230 0.382http://dx.doi.org/10.1016/j.hkjn.2015.08.129
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Clinical Characteristics and Outcomes of Lupus Podocytopathy with
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Objectives: To investigate the clinical characteristics and outcomes of lupus
podocytopathy with different glomerular lesions.
Methods: Lupus podocytopathy (defined as foot process effacement 50% of
the glomerular capillary loop area without deposits in capillary wall under
electron microscopy) was screened from 3750 lupus nephritis patients in
Nanjing Jinling hospital between January 2000 and December 2013 and
were divided into 3 groups including minimal change disease (MCD), mesan-
gial proliferation (MP) and focal segmental glomerulosclerosis (FSGS) by light
microscopy. The clinical characteristics, treatment response and outcomes
were retrospectively studied and compared among 3 groups.
Results: 53 patients (1.41%) were re-classified as lupus podocytopathy,
including 13 with MCD, 31 with MP and 9 with FSGS. 50 (94.3%) patients pre-
sented with nephrotic syndrome, 3 (5.7%) patients showed non-nephrotic
proteinuria, 17 (32.1%) patients had concomitant AKI. The incidence of AKI
was significantly higher in FSGS group (77.8%) than in MCD (23.1%) and MP
(22.6%) groups (P< 0.01). Low serum C3 was more frequently seen in FSGS
(88.9%) and MP groups (83.9%) than in MCD group (23.1%, P< 0.05). No dif-
ference was observed in foot process effacement among the 3 groups.
More patients had severe acute tubulointerstitial lesions in FSGS group
(77.8%) than in MCD (7.7%) and MP (22.6%) groups (P< 0.01). 50 (94.3%) pa-
tients achieved remission after immunosuppressive induction treatment,
among whom 41 (77.4%) had complete remission (CR). The CR rate in FSGS
group (22.2%) was significantly lower than in MCD (92.3%) and MP (87.1%)
groups (P< 0.01). During follow-up for 44 months (9e125 months), 29
(54.7%) patients had renal relapse, no patient died or developed end stage
renal disease.
Conclusion: Lupus podocytopathy with different glomerular lesions showed
variable clinical characteristics with benign outcomes. Patients with MCD
and MP shared similar clinical features, which were different from patients
with FSGS in terms of AKI incidence, tubular injury severity and response to
immunosuppressive treatment.Serum complement C4 (g/L) 0.1450.124 0.1340.104 0.278
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.
Table 3. Baseline clinical features of LN patients with subclass IV-S and
IV-G.
IV-S IV-G P value
Patients (n, %) 117 (20.9%) 442 (79.1%)
Female (n, %) 104 (88.9%) 389 (88.0%) 0.873
LN onset age (years) 32.28.2 30.88.4 0.108
Mean arterial pressure
(mmHg)
98.013.0 102.114.8 0.004
Haemoglobin (g/dl) a 9.21.9 8.82.0 0.124
Haematuria (104cells/ml) 60.0
(10.5-244.0)
100.0
(15.0-271.3)
0.419
24-h urinary protein (g/24h) 2.751.76 3.593.13 <0.001
Serum creatinine (mg/dl) a 1.361.30 1.511.33 0.254
Serum complement C3 (g/L) 0.5970.297 0.4810.256 <0.001
Serum complement C4 (g/L) 0.1630.123 0.1400.123 0.071
ANCA positive rate (％) 9.5% 5.2% 0.130
a Conversion factors for units: serum creatinine in mg/dl to mmol/l,
88.4; haemoglobin in g/dl to g/l, 0.1.http://dx.doi.org/10.1016/j.hkjn.2015.08.130
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Objective: To observe the discrepancy between class III and class III+V, be-
tween class IV and class IV+V, and between subclass IV-S and IV-G on clinico-
pathological features and renal outcomes and explore the pathological
lesions associated with poor renal outcomes in patients with different
classes.
Methods: The records of all adult patients with biopsy-proven proliferative
lupus nephritis followed for at least 1 year were reviewed. All patients
were pathologically classified according to the 2003 ISN/RPS classification
of lupus nephritis and each pathological lesion was semiquantatively scored.
Results: Patients with class III+V (class IV+V) presented with more severe
proteinuria and chronic pathological lesions and milder acute pathological
lesions than patients with class III (class IV) (Tables 1e2, 4e5); patients
with subclass IV-G presented with more severe hypertension, proteinuriaand hypocomplementemia, lower ANCA positivity rate, more severe glomer-
ular cell proliferation and hyaline deposit, and milder fibrinoid necrosis and
crescent than patients with subclass IV-S (Tables 3, 6). The renal outcomes
between patients with class III and class III+V, between class IV and class
IV+V, and between subclass IV-S and subclass IV-G were not different respec-
tively (Figures 1e3). Global glomerulosclerosis, cellular crescent, fibrous
crescent, glomerular cell proliferation, tubular acute injury, interstitial
inflammation and TMA were predictors for ESRD.
